NCT02478333 - A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG

ALS-008176 (250 mg)

Participants will receive ALS-008176, 250 mg oral suspension once on Day 1 under fasted conditions.

DRUG

ALS-008176 (500 mg)

Participants will receive ALS-008176, 500 mg oral suspension once on Day 1 under fasted conditions.

DRUG

ALS-008176 (750 mg)

Participants will receive ALS-008176, 750 mg oral suspension once on Day 1 under fasted conditions.

OTHER

Placebo

Participants will receive placebo oral suspension once on Day 1 under fasted conditions.

Trial Locations (1)

Fukuoka